Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS San Raffaele
About this trial
Adult patients with chronic lymphocytic leukemia (CLL), splenic marginal-zone lymphoma (SMZL) and hairy cell leukemia (HCL) followed at participating clinical sites will be enrolled and undergo sampling of additional amount of blood during the blood draws performed as part of standard clinical care.
The project aims to develop and validate innovative patient-derived 3D bioprinted models that faithfully reproduce the key microenvironments of lymphoid tissues, enabling a more physiologically relevant study of mature B-cell malignancies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years
Diagnosis of CLL, SMZL or HCL
Participant is willing and able to autonomously give informed consent for participation in the study.
Disqualifiers
None
Trial population
Adult patients with CLL, SMZL, HCL followed at participating clinical sites
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
64 Participants
are grouped into 3 trial groupsGroup A: CLL
Group B: SMZL
Group C: HCL
Trial outcomes
Primary outcomes
1
To generate 3D culture models from patients with CLL, SMZL, HCL
≥50% 3D culture models generated from patients with CLL, SMZL and HCL, defined as cell viability \>80% per sample in standard condition
Time frame
36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
IRCCS San Raffaele
Lead sponsor
Ministry of Health, Italy
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: